After 340B Hearing and New Bills Emerging; The Likely Path Forward
By Ted Slafsky
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June 4th House Energy & Commerce (E&C) Oversight and Investigations Subcommittee hearing, there had not been a hearing specifically devoted to the 340B program since March 2018.
This is due to the fact that most in Congress would prefer to avoid issues that have two powerful interest groups with often diametrically opposite opinions on key matters. What has been the general approach of Congress when they are called upon to address the tricky, often contentious issues facing 340B stakeholders? Let the Health Resources and Services Administration deal with it, or if need be, the federal courts. Read More >
We simplify the complex process of maintaining 340B program compliance resulting in critical 340B cost savings for our customers. Hundreds of integrated healthcare systems, acute-care hospitals, community health centers, federally-qualified health centers, pharmacies, and other 340B-eligible covered entities throughout the United States rely on Verity 340B® software and services to successfully manage their 340B program.
This post is related to:
Distribution: 340B Solutions, 340B Management Systems Practice Setting: Health System Pharmacy Resources
